FAKTOR YANG BERHUBUNGAN DENGAN KELENGKAPAN TERAPI PENCEGAHAN TUBERKULOSIS SENSITIF OBAT DI KOTA JAKARTA BARAT TAHUN 2020 - 2023
DOI:
https://doi.org/10.31004/prepotif.v9i1.43132Keywords:
implementasi program, kohort retrospektif, SITB, TBC laten, terapi pencegahan tuberkulosis (TPT)Abstract
Tatalaksana TBC laten sesuai rekomendasi WHO tahun 2018 dengan Program Terapi Pencegahan Tuberkulosis (TPT) baru dilaksanakan tahun 2020 di Indonesia. Capaian Angka Kelengkapan TPT di DKI Jakarta 76.7% dari target 80%. Studi ini untuk memberikan gambaran karakteristik penerima TPT di Kota Jakarta Barat, termasuk faktor yang berhubungan kelengkapan TPT sensitif obat. Penelitian ini menggunakan desain kohort retrospektif dengan sumber data sekunder dengan total sampel 890 memenuhi kriteria inklusi dan eksklusi dari total 1555 penerima TPT dari Sistem Informasi Tuberkulosis (SITB) tahun 2020 - 2023. Hasil univariat didapatkan proporsi kelengkapan TPT Jakarta Barat adalah 94%. Hasil analisis multivariat didapatkan hasil peluang kelengkapan terapi signifikan pada waktu setelah 72 hari terapi untuk hubungan durasi pemberian TPT 3 bulan (aHR: 8.68; 95% CI: 6.29 – 11.97) dibanding paduan 6 bulan, jenis pemberi layanan TPT puskesmas lebih berpeluang lengkap (aHR: 1.76; 95% CI: 1.06–2.89) dibanding pasien rumah sakit, dan bila pemeriksaan TST positif (aHR: 1.26: 95% CI 1.05 – 1.49) dibanding pasien yang tidak dilakukan TST. Kesimpulan dari penelitian ini yakni penguatan implementasi program TPT secara holistic perlu dilakukan dengan mempertimbangkan alokasi dukungan sesuai karakteristik pasien yang lebih berpeluang melengkapi TPT, agar program TPT ini dapat berjalan seefektif dan seefisien mungkin.References
Adepoju, V. A., Adelekan, A., Agbaje, A., Quaitey, F., Ademola-Kay, T., Udoekpo, A. U., & Sokoya, O. D. (2023). Completion of 6-mo isoniazid preventive treatment among eligible under six children: A cross-sectional study, Lagos, Nigeria. World Journal of Clinical Cases, 11(1), 104–115. https://doi.org/10.12998/wjcc.v11.i1.104
Ai, J.-W., Ruan, Q.-L., Liu, Q.-H., & Zhang, W.-H. (2016). Updates on the risk factors for latent tuberculosis reactivation and their managements. Emerging Microbes & Infections, 5(1), 1–8. https://doi.org/10.1038/emi.2016.10
Bea, S., Lee, H., Kim, J. H., Jang, S. H., Son, H., Kwon, J.-W., & Shin, J.-Y. (2021). Adherence and Associated Factors of Treatment Regimen in Drug-Susceptible Tuberculosis Patients. Frontiers in Pharmacology, 12, 625078. https://doi.org/10.3389/fphar.2021.625078
Budiyani, P. I. R., Djuwita, R., Mahkota, R., & Handayani, D. (2024). Factors Associated with Successful Drug Susceptible Tuberculosis Treatment among Tuberculosis – Human Immunodeficiency Virus Patients in DKI Jakarta Province 2020 – 2022. Asian Journal of Engineering, Social and Health, 3(4), 702–713. https://doi.org/10.46799/ajesh.v3i4.287
Campbell, J. I., Sandora, T. J., & Haberer, J. E. (2021). A scoping review of paediatric latent tuberculosis infection care cascades: Initial steps are lacking. BMJ Global Health, 6(5), e004836. https://doi.org/10.1136/bmjgh-2020-004836
Choi, H., Lee, M., Chen, R. Y., Kim, Y., Yoon, S., Joh, J. S., Park, S. K., Dodd, L. E., Lee, J., Song, T., Cai, Y., Goldfeder, L. C., Via, L. E., Carroll, M. W., Barry, C. E., & Cho, S.-N. (2014). Predictors of pulmonary tuberculosis treatment outcomes in South Korea: A prospective cohort study, 2005-2012. BMC Infectious Diseases, 14(1), 360. https://doi.org/10.1186/1471-2334-14-360
Dye, C., Glaziou, P., Floyd, K., & Raviglione, M. (2013). Prospects for Tuberculosis Elimination. Annual Review of Public Health, 34(1), 271–286. https://doi.org/10.1146/annurev-publhealth-031912-114431
Global Tuberculosis Report 2023 (1st ed). (2023). World Health Organization.
Kemenkes RI (2020) Isi-Juknis-ILTB-FINAL-ok_published.pdf. (n.d.). Retrieved February 11, 2025, from https://www.tbindonesia.or.id/wp-content/uploads/2021/01/Isi-Juknis-ILTB-FINAL-ok_published.pdf
Kim, S., Thal, R., & Szkwarko, D. (2023). Management of Latent Tuberculosis Infection. JAMA, 329(5), 421–422. https://doi.org/10.1001/jama.2022.24362
Kemenkes RI (2023) Laporan-Tahunan-Program-TBC-2022. (n.d.). Retrieved February 11, 2025, from https://www.tbindonesia.or.id/wp-content/uploads/2023/01/Laporan-Tahunan-Program-TBC-2022.pdf
McClintock, A. H., Eastment, M., McKinney, C. M., Pitney, C. L., Narita, M., Park, D. R., Dhanireddy, S., & Molnar, A. (2017). Treatment completion for latent tuberculosis infection: A retrospective cohort study comparing 9 months of isoniazid, 4 months of rifampin and 3 months of isoniazid and rifapentine. BMC Infectious Diseases, 17(1), 146. https://doi.org/10.1186/s12879-017-2245-8
Moro, R. N., Borisov, A. S., Saukkonen, J., Khan, A., Sterling, T. R., Villarino, M. E., Scott, N. A., Shang, N., Kerrigan, A., & Goldberg, S. V. (2016). Factors Associated With Noncompletion of Latent Tuberculosis Infection Treatment: Experience From the PREVENT TB Trial in the United States and Canada. Clinical Infectious Diseases, 62(11), 1390–1400. https://doi.org/10.1093/cid/ciw126
Sandgren, A., Vonk Noordegraaf-Schouten, M., van Kessel, F., Stuurman, A., Oordt-Speets, A., & van der Werf, M. J. (2016). Initiation and completion rates for latent tuberculosis infection treatment: A systematic review. BMC Infectious Diseases, 16(1), 204. https://doi.org/10.1186/s12879-016-1550-y
Santos, J. C., Silva, J. B., Rangel, M. A., Barbosa, L., & Carvalho, I. (2020). Preventive therapy compliance in pediatric tuberculosis – A single center experience. Pulmonology, 26(2), 78–83. https://doi.org/10.1016/j.pulmoe.2019.06.002
Stockbridge, E. L., Miller, T. L., Carlson, E. K., & Ho, C. (2018). Predictors of latent tuberculosis infection treatment completion in the US private sector: An analysis of administrative claims data. BMC Public Health, 18(1), 662. https://doi.org/10.1186/s12889-018-5578-3
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Indah Budiarti, Syahrizal Syarif
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work’s authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal’s published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
